- Reuters•7 hours ago
Eli Lilly and Co on Tuesday reported better-than-expected quarterly sales, fueled by newer drugs, and predicted average annual revenue growth of at least 5 percent through the end of the decade due to its growing roster of medicines. The Indianapolis drugmaker, whose earnings growth resumed last year after three years of tumbling sales caused by competition from generic drugs, said investors can count on annual dividend increases in 2016 and beyond. Revenue rose 9 percent to $5.4 billion in the second quarter, topping Wall Street estimates of $5.15 billion.
- Insider Monkey•9 hours ago
With the earnings season ongoing, the US stock market is mixed with Dow Jones trading lower, while S&P 500 and NASDAQ have inched up. Among the stocks traders are talking about are BP plc (ADR) (NYSE:BP), Valero Energy Corporation (NYSE:VLO), CONSOL Energy Inc. (NYSE:CNX), Mobileye NV (NYSE:MBLY), and Eli Lilly and Co (NYSE:LLY). Let’s examine why each […]
Eli Lilly and CompanyNYSE
After hours: 82.900.81 (0.99%) as of 5:55 PM EDT
|Bid||82.08 x 2500|
|Ask||82.09 x 1500|
|52wk Range||67.88 - 92.85|
|Day's Range||81.64 - 83.34|
|Avg Vol (3m)||4,193,580|
As of 4:00 PM EDT. Market closed.